Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 228Neoplasm Metastasis 19Neoplasms 9Breast Neoplasms, Male 7Breast Diseases 7Ovarian Neoplasms 4Carcinoma, Intraductal, Noninfiltrating 4Recurrence 3Obesity 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Carcinoma In Situ 3Breast Cancer Metastatic 3Advanced Breast Cancer 3Prostatic Neoplasms 2Neoplasms by Site 2Multiple Endocrine Neoplasia Type 1 2Carcinoma, Renal Cell 2Bulbo-Spinal Atrophy, X-Linked 2Arthralgia 2Vitamin D Deficiency 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sleep Wake Disorders 1Skin Diseases 1Sexuality 1

Interventions

trastuzumab biosimilar HLX02 1exemestane 1X-Rays 1Trastuzumab 1Taxes 1TVB-2640 1Specimen Handling 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Magnetic Resonance Spectroscopy 1Letrozole 1Fulvestrant 1Disulfides 1CT-P6 1Biopsy 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Breast Carcinoma × exemestane × Clear all
NCT03179904 2026-05-05

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

Mayo Clinic

Phase 2 Active not recruiting
17 enrolled 10 charts
Breast

Advanced Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡